.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,545,637

« Back to Dashboard

Details for Patent: 5,545,637

Title: Process for preparing pharmaceutical compositions containing crystalline anhydrous mycophenolate mofetil salts
Abstract:The crystalline anhydrous salt formed by complexing mycophenolate mofetil with an anion selected from the group chloride, sulfate, phosphate and acetate (in particular the hydrochloride salt), and pharmaceutical compositions, intravenous formulations and a kit thereof, and associated methods of treatment.
Inventor(s): Fu; Roger C. (Saratoga, CA), Leung; De-Mei (Los Altos, CA), Fleitman; Jeffrey S. (Sunnyvale, CA), Rizzolio; Michele C. (Durham, NC), Miksztal; Andrew R. (Menlo Park, CA)
Assignee: Syntex (U.S.A.) Inc. (Palo Alto, CA)
Filing Date:Jun 02, 1995
Application Number:08/459,991
Claims:1. A process for preparing a pharmaceutical composition suitable for preparing an aqueous intravenous formulation of mycophenolate mofetil, the process comprising:

a) compounding mycophenolate mofetil, an acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and acetic acid, and a pharmaceutically acceptable excipient to form a bulking solution having a pH of about 3.2 to 3.6,

b) the bulking solution into a container for lyophilization, and

c) lyophilizing the loaded container.

2. The process of claim 1 wherein said acid is hydrochloric acid.

3. The process of claim 1 wherein said pharmaceutically acceptable excipient comprises a bulking agent, a clarifying agent, and/or a buffering agent.

4. The process of claim 3 wherein said pharmaceutically acceptable excipient comprises polysorbate 80.

5. The process of claim 4 wherein said pharmaceutically acceptable excipient comprises polysorbate 80 and citric acid.

6. The process of claim 1 wherein said lyophilizing step comprises sequentially:

a) decreasing the temperature from about 25.degree. C. to about -40.degree. C.;

b) decreasing the pressure to about 100 mTorr;

c) increasing the temperature from about -40.degree. C. to about 70.degree. C.; and

d) decreasing the temperature from about 70.degree. C. to about 25.degree. C.

7. The process of claim 6 wherein said lyophilizing step comprises sequentially:

a) decreasing the temperature from about 25.degree. C. to about -10.degree. C. at a ramp rate of about -0.25.degree. C./min;

b) maintaining temperature at about -10.degree. C. for about 2 hours and 30 minutes;

c) decreasing the temperature from about -10.degree. C. to about -40.degree. C. at a ramp rate of about -0.25.degree. C./min;

d) decreasing the pressure to about 100 mTorr;

e) increasing the temperature from about -40.degree. C. to about -16.degree. C. at a ramp rate of about 0.05.degree. C./min;

f) increasing the temperature from about -16.degree. C. to about 70.degree. C. at a ramp rate of about 0.20 .degree. C./min; and

g) decreasing the temperature from about 70.degree. C. to about 25.degree. C. at a ramp rate of about -0.25.degree. C./min.

8. A process for preparing a pharmaceutical composition suitable for preparing an aqueous intravenous formulation of mycophenolate mofetil, the process comprising:

a) compounding mycophenolate mofetil, hydrochloric acid, polysorbate 80, citric acid, ethanol, and water to form a bulking solution having a pH Of about 3.2 to 3.6,

b) loading the bulking solution into a container for lyophilization, and

c) lyophilizing the loaded container.

9. The process of claim 8 wherein said lyophilizing step comprises sequentially:

a) decreasing the temperature from about 25.degree. C. to about -40.degree. C.;

b) decreasing the pressure to about 100 mTorr;

c) increasing the temperature from about -40.degree. C. to about 70.degree. C.; and

d) decreasing the temperature from about 70.degree. C. to about 25.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc